Phase II feasibility study of high dose epirubicin-based regimens for untreated patients with small-cell lung cancer.

Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer.

Phase II study of sulofenur (LY186641) in untreated patients with extensive small cell lung cancer.

Randomized phase II trial of high-dose 4'-epi-doxorubicin + cyclophosphamide versus high-dose 4'-epi-doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer.

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer.

Phase II studies: untreated breast cancer patients.

High-dose epirubicin for untreated patients with advanced tumours: a phase I study.

Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer.

Phase II clinical study of high-dose toremifene in patients with advanced breast cancer.

$Phase I-II study of high-dose etoposide in patients with refractory breast cancer.$
Phase I-II study of high-dose etoposide in patients with refractory breast cancer.

A phase II study of high dose epirubicin in unresectable non small cell lung cancer.

Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer.

Phase II study of high-dose epirubicin in non-small cell lung cancer.

Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.

Phase II study of trimetrexate and cyclophosphamide in previously untreated patients with inoperable non-small cell lung cancer.

II study of amrubicin and nedaplatin in patients with untreated, advanced, non-small cell lung cancer.

Phase II study of 4-demethoxydaunorubicin in previously untreated extensive disease non-small cell lung cancer.

Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study.

Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group.

Carboplatin activity in untreated metastatic breast cancer patients--results of a phase II study.

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group.

Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.

A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small-cell lung cancer (NSCLC).

A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases.

Suggest Documents

Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer.

Phase II study of sulofenur (LY186641) in untreated patients with extensive small cell lung cancer.

Randomized phase II trial of high-dose 4'-epi-doxorubicin + cyclophosphamide versus high-dose 4'-epi-doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer.

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer.

Phase II studies: untreated breast cancer patients.

High-dose epirubicin for untreated patients with advanced tumours: a phase I study.

Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer.

Phase II clinical study of high-dose toremifene in patients with advanced breast cancer.

Phase I-II study of high-dose etoposide in patients with refractory breast cancer.

A phase II study of high dose epirubicin in unresectable non small cell lung cancer.

Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer.

Phase II study of high-dose epirubicin in non-small cell lung cancer.

Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.

Phase II study of trimetrexate and cyclophosphamide in previously untreated patients with inoperable non-small cell lung cancer.

II study of amrubicin and nedaplatin in patients with untreated, advanced, non-small cell lung cancer.

Phase II study of 4-demethoxydaunorubicin in previously untreated extensive disease non-small cell lung cancer.

Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study.

Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group.

Carboplatin activity in untreated metastatic breast cancer patients--results of a phase II study.

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group.

Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.

A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small-cell lung cancer (NSCLC).

A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases.

Phase II feasibility study of high dose epirubicin-based regimens for untreated patients with small-cell lung cancer.

Recommend Documents

Follow Us